June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Systemic and local treatment with TG101209, a combined JAK2 and bromodomain BRD4-1 inhibitor, can diminish ocular disease progression in a murine model of graft-versus-host disease
Author Affiliations & Notes
  • Hazem Mousa
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • nadim S. azar
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Liwen Lin
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Seitaro Komai
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Manuel Quiroga-Garza
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Ricardo G Blanco Ortiz
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Matias Soifer
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
    National Eye Institute, Bethesda, Maryland, United States
  • Jose Echegaray
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Robert B Levy
    Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Florida, United States
  • Victor L Perez
    Foster Center for Ocular Immunology, Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Hazem Mousa None; nadim azar None; Liwen Lin None; Seitaro Komai None; Manuel Quiroga-Garza None; Ricardo Blanco Ortiz None; Matias Soifer None; Jose Echegaray None; Robert Levy Kimera Labs, NightHawk Biosciences, Code C (Consultant/Contractor), NIH, NightHawk Biosciences, Code F (Financial Support); Victor Perez Dompe, Novartis, Kiora, Regentree, Santen, Trefoil, Code C (Consultant/Contractor), Alcon, EBN, NIH, Code F (Financial Support)
  • Footnotes
    Support  NIH/NEI R01EY030283 (Levy, Perez), NIH/NEI R01EY024485 (Levy, Perez), Duke NIH Core Grant P30EY005722, and Duke Research to Prevent Blindness Unrestricted Grant
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1936. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hazem Mousa, nadim S. azar, Liwen Lin, Seitaro Komai, Manuel Quiroga-Garza, Ricardo G Blanco Ortiz, Matias Soifer, Jose Echegaray, Robert B Levy, Victor L Perez; Systemic and local treatment with TG101209, a combined JAK2 and bromodomain BRD4-1 inhibitor, can diminish ocular disease progression in a murine model of graft-versus-host disease. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1936.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To test the local or systemic use of TG101209, a combined JAK2 and bromodomain BRD4-1 inhibitor, in the prevention of disease development in a mouse model of graft-versus-host disease (GVHD)

Methods : In mice, an allogeneic GVHD model was established by transferring bone marrow (BM) and purified splenic T cells from C57BL/6J mice into irradiated C3-SW.H2b mice. Diseased groups consisted of: (1) No treatment (BM+T); (2) subconjunctival (SC) TG101209; (3) intraperitoneal (IP) TG101209; and (4) mice that received BM only (BMO). Mice were assessed for systemic and ocular disease across the 21-day post-transplantation period. Systemic disease was assessed using a composite score (0-12) of weight loss, activity, posture, fur texture, alopecia, skin integrity, and diarrhea. Ocular disease was assessed using eyelid edema (0-2), meibomian gland (MG) atrophy (% atrophy), and corneal epitheliopathy (staining fluorescence).

Results : Mice were assessed across the 21-day post-transplant period (n=12/group). Compared to BM+T mice, a significantly reduced median systemic disease score was noted on day 21 for the IP TG101209 and the BMO groups (4.25 and 0 vs 7.75, respectively; p<0.05) but not the SC TG101209 group (8 vs 7.75, p>0.1). Regarding ocular disease on day 21, compared to BM+T mice, a significantly reduced median eyelid edema score was noted for the BMO (0 vs 3), SC TG101209 (1.5 vs 3), and IP TG101209 (1.25 vs 3) groups (all p<0.05). Median fluorescein corneal staining index on day 21 was significantly lower for the BMO (4 vs 22), SC TG101209 (12.5 vs 22), and IP TG101209 (12 vs 22) groups compared to BM+T mice (all p<0.05). An MG atrophy of more than 50% was noted in 10/12 (80%) of the BM+T mice, significantly higher than that of the BMO (0%), SC TG101209 (3/12, 25%), and the IP TG101209 (2/12, 16.6%) (all p<0.05). No treatment complications were noted.

Conclusions : Systemic treatment with TG101209 reduced systemic and ocular GVHD development compared to no treatment. Despite not affecting systemic disease development, local treatment with TG101209 reduced ocular GVHD progression compared to no treatment. These findings highlight the safety and therapeutic potential of JAK2 with BRD4-1 inhibition in the treatment of ocular surface immune conditions. Additional testing is required for a more standardized comparison.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×